Identification of novel PTP1B inhibitors by pharmacophore based virtual screening, scaffold hopping and docking.

[1]  A. Saxena,et al.  Rohitukine inhibits in vitro adipogenesis arresting mitotic clonal expansion and improves dyslipidemia in vivo[S] , 2014, Journal of Lipid Research.

[2]  Zhanjun Jia,et al.  PPARs and Metabolic Syndrome , 2014, PPAR research.

[3]  David Carling,et al.  AMPK, insulin resistance, and the metabolic syndrome. , 2013, The Journal of clinical investigation.

[4]  A. Saxena,et al.  Identification of novel 2-((1-(benzyl(2-hydroxy-2-phenylethyl)amino)-1-oxo-3-phenylpropan-2-yl)carbamoyl)benzoic acid analogues as BMP-2 stimulators. , 2012, Journal of medicinal chemistry.

[5]  Akansha Mishra,et al.  Antidiabetic and antidyslipidemic activities of Cuminum cyminum L. in validated animal models , 2011, Medicinal Chemistry Research.

[6]  A. Saxena,et al.  Synthesis and 2D QSAR of O-sulphonated β-aminols derivatives as novel antifungal and antibacterial agents. , 2011, Bioorganic & medicinal chemistry letters.

[7]  J. Wouters,et al.  Tryptophan 2,3-dioxygenase (TDO) inhibitors. 3-(2-(pyridyl)ethenyl)indoles as potential anticancer immunomodulators. , 2011, Journal of medicinal chemistry.

[8]  A.K. Gupta,et al.  Pharmacophore modelling, molecular docking and virtual screening for EGFR (HER 1) tyrosine kinase inhibitors , 2011, SAR and QSAR in environmental research.

[9]  Aamir Nazir,et al.  Novel carbamates as orally active acetylcholinesterase inhibitors found to improve scopolamine-induced cognition impairment: pharmacophore-based virtual screening, synthesis, and pharmacology. , 2010, Journal of medicinal chemistry.

[10]  M. Roitman,et al.  Inhibition of PTP1B by Trodusquemine (MSI‐1436) Causes Fat‐specific Weight Loss in Diet‐induced Obese Mice , 2010, Obesity.

[11]  Róbert Kun,et al.  Hydrophobization of bovine serum albumin with cationic surfactants with different hydrophobic chain length. , 2010, Colloids and surfaces. B, Biointerfaces.

[12]  Liqun Zhang,et al.  Spectroscopic studies on the interaction and sonodynamic damage of neutral red (NR) to bovine serum albumin (BSA) , 2010 .

[13]  A. Combs.  Recent advances in the discovery of competitive protein tyrosine phosphatase 1B inhibitors for the treatment of diabetes, obesity, and cancer. , 2010, Journal of medicinal chemistry.

[14]  Gaochao Zhou,et al.  AMPK: an emerging drug target for diabetes and the metabolic syndrome. , 2009, Cell metabolism.

[15]  N. Neamati,et al.  Amide-containing diketoacids as HIV-1 integrase inhibitors: synthesis, structure-activity relationship analysis, and biological activity. , 2009, Bioorganic & medicinal chemistry.

[16]  C. Holmes,et al.  PTP1B inhibitors: synthesis and evaluation of difluoro-methylenephosphonate bioisosteres on a sulfonamide scaffold. , 2008, Bioorganic & medicinal chemistry letters.

[17]  Aiqin Gong,et al.  A fluorescence spectroscopic study of the interaction between epristeride and bovin serum albumine and its analytical application. , 2007, Talanta.

[18]  A. Moretto,et al.  Structure-based optimization of protein tyrosine phosphatase 1B inhibitors: from the active site to the second phosphotyrosine binding site. , 2007, Journal of medicinal chemistry.

[19]  Hai-zhuan Lin,et al.  Nitroaniline Isomers Interaction with Bovine Serum Albumin and Toxicological Implications , 2007, Journal of Fluorescence.

[20]  Seokjoon Lee,et al.  Recent development of small molecular specific inhibitor of protein tyrosine phosphatase 1B , 2007, Medicinal research reviews.

[21]  B. Burgering,et al.  Live longer through PHAsting. , 2007, Cell metabolism.

[22]  Anshuman Dixit,et al.  Computer-Aided Drug Design: Integration of Structure-Based and Ligand-Based Approaches in Drug Design , 2007 .

[23]  D. Joseph-McCarthy,et al.  Probing acid replacements of thiophene PTP1B inhibitors. , 2007, Bioorganic & medicinal chemistry letters.

[24]  Sheng Zhang,et al.  PTP1B as a drug target: recent developments in PTP1B inhibitor discovery. , 2007, Drug discovery today.

[25]  Richard Wynn,et al.  Structural Insights into the Design of Nonpeptidic Isothiazolidinone-containing Inhibitors of Protein-tyrosine Phosphatase 1B* , 2006, Journal of Biological Chemistry.

[26]  François Durant,et al.  Structure-based pharmacophore of COX-2 selective inhibitors and identification of original lead compounds from 3D database searching method. , 2006, European journal of medicinal chemistry.

[27]  D. Joseph-McCarthy,et al.  Monocyclic thiophenes as protein tyrosine phosphatase 1B inhibitors: capturing interactions with Asp48. , 2006, Bioorganic & medicinal chemistry letters.

[28]  M. Bower,et al.  Potent benzimidazole sulfonamide protein tyrosine phosphatase 1B inhibitors containing the heterocyclic (S)-isothiazolidinone phosphotyrosine mimetic. , 2006, Journal of medicinal chemistry.

[29]  Young Ho Kim,et al.  Inhibition of protein tyrosine phosphatase 1B by diterpenoids isolated from Acanthopanax koreanum. , 2006, Bioorganic & medicinal chemistry letters.

[30]  Thierry Langer,et al.  The discovery of new 11beta-hydroxysteroid dehydrogenase type 1 inhibitors by common feature pharmacophore modeling and virtual screening. , 2006, Journal of medicinal chemistry.

[31]  Miklos Feher,et al.  Consensus scoring for protein-ligand interactions. , 2006, Drug discovery today.

[32]  René Thomsen,et al.  MolDock: a new technique for high-accuracy molecular docking. , 2006, Journal of medicinal chemistry.

[33]  A. Moretto,et al.  Bicyclic and tricyclic thiophenes as protein tyrosine phosphatase 1B inhibitors. , 2006, Bioorganic & medicinal chemistry.

[34]  C. Moody,et al.  Discovery and structure-activity relationships of novel sulfonamides as potent PTP1B inhibitors. , 2005, Bioorganic & medicinal chemistry letters.

[35]  Katherine R Schiller,et al.  Tyrosine phosphatases as regulators of skeletal development and metabolism , 2005, Journal of cellular biochemistry.

[36]  Karl Blom,et al.  Structure-based design and discovery of protein tyrosine phosphatase inhibitors incorporating novel isothiazolidinone heterocyclic phosphotyrosine mimetics. , 2005, Journal of medicinal chemistry.

[37]  Thierry Langer,et al.  Discovery of high-affinity ligands of σ1 receptor, ERG2, and emopamil binding protein by pharmacophore modeling and virtual screening , 2005 .

[38]  Leonardo Pardo,et al.  A three-dimensional pharmacophore model for 5-hydroxytryptamine6 (5-HT6) receptor antagonists. , 2005, Journal of medicinal chemistry.

[39]  B. Kennedy,et al.  Therapeutic strategies for targeting PTP1B in diabetes , 2005 .

[40]  Osman Güner,et al.  Pharmacophore modeling and three dimensional database searching for drug design using catalyst: recent advances. , 2004, Current medicinal chemistry.

[41]  R. Ahima,et al.  A novel aminosterol reverses diabetes and fatty liver disease in obese mice. , 2004, Journal of hepatology.

[42]  Joanna M. Sasin,et al.  Protein Tyrosine Phosphatases in the Human Genome , 2004, Cell.

[43]  Thierry Langer,et al.  Impact of Scoring Functions on Enrichment in Docking-Based Virtual Screening: An Application Study on Renin Inhibitors , 2004, J. Chem. Inf. Model..

[44]  G. Barish,et al.  PPARs and the complex journey to obesity , 2004, Nature Medicine.

[45]  C. Bayly,et al.  Structure based design of a series of potent and selective non peptidic PTP-1B inhibitors. , 2004, Bioorganic & medicinal chemistry letters.

[46]  C. Bayly,et al.  The structural basis for the selectivity of benzotriazole inhibitors of PTP1B. , 2003, Biochemistry.

[47]  Renxiao Wang,et al.  Comparative evaluation of 11 scoring functions for molecular docking. , 2003, Journal of medicinal chemistry.

[48]  G. Mcmahon,et al.  Structure-based design and discovery of novel inhibitors of protein tyrosine phosphatases. , 2003, Bioorganic & medicinal chemistry.

[49]  M. Ibberson,et al.  Protein tyrosine phosphatases as drug targets: PTP1B and beyond , 2002, Expert opinion on therapeutic targets.

[50]  Wolfgang Sippl,et al.  Development of biologically active compounds by combining 3D QSAR and structure-based design methods , 2002, J. Comput. Aided Mol. Des..

[51]  J. Ermolieff,et al.  Protein tyrosine phosphatase 1B inhibitors for diabetes , 2002, Nature Reviews Drug Discovery.

[52]  J. Waring,et al.  Protein tyrosine phosphatase 1B reduction regulates adiposity and expression of genes involved in lipogenesis. , 2002, Diabetes.

[53]  R. Ahima,et al.  Appetite suppression and weight reduction by a centrally active aminosterol. , 2002, Diabetes.

[54]  Claude Dufresne,et al.  The structure of PTP-1B in complex with a peptide inhibitor reveals an alternative binding mode for bisphosphonates. , 2002, Biochemistry.

[55]  M. Blaskovich,et al.  Recent discovery and development of protein tyrosine phosphatase inhibitors , 2002 .

[56]  R. Unger,et al.  Protein tyrosine phosphatase 1B: a potential leptin resistance factor of obesity. , 2002, Developmental cell.

[57]  P G Drake,et al.  Structural and Evolutionary Relationships among Protein Tyrosine Phosphatase Domains , 2001, Molecular and Cellular Biology.

[58]  S. Wälchli,et al.  Pulling strings below the surface , 2001, Endocrine.

[59]  T. Hunter,et al.  Oncogenic kinase signalling , 2001, Nature.

[60]  M. Zasloff,et al.  A spermine-coupled cholesterol metabolite from the shark with potent appetite suppressant and antidiabetic properties , 2001, International Journal of Obesity.

[61]  B. Neel,et al.  Combinatorial control of the specificity of protein tyrosine phosphatases. , 2001, Current opinion in cell biology.

[62]  M. Tabak,et al.  Spectroscopic studies on the interaction of bovine (BSA) and human (HSA) serum albumins with ionic surfactants. , 2000, Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy.

[63]  B. Kennedy,et al.  Protein tyrosine phosphatase-1B in diabetes. , 2000, Biochemical pharmacology.

[64]  J. Chernoff,et al.  Down-regulation of Insulin Signaling by Protein-tyrosine Phosphatase 1B Is Mediated by an N-terminal Binding Region* , 2000, The Journal of Biological Chemistry.

[65]  Young-Bum Kim,et al.  Increased Energy Expenditure, Decreased Adiposity, and Tissue-Specific Insulin Sensitivity in Protein-Tyrosine Phosphatase 1B-Deficient Mice , 2000, Molecular and Cellular Biology.

[66]  T. Hunter,et al.  Signaling—2000 and Beyond , 2000, Cell.

[67]  B. Kennedy,et al.  Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene. , 1999, Science.

[68]  T R Burke,et al.  Structural basis for inhibition of the protein tyrosine phosphatase 1B by phosphotyrosine peptide mimetics. , 1998, Biochemistry.

[69]  É. Hajduch,et al.  Fructose uptake in rat adipocytes: GLUT5 expression and the effects of streptozotocin-induced diabetes , 1998, Diabetologia.

[70]  B. Goldstein,et al.  Regulation of the insulin signalling pathway by cellular protein-tyrosine phosphatases , 1998, Molecular and Cellular Biochemistry.

[71]  D S Lawrence,et al.  Identification of a second aryl phosphate-binding site in protein-tyrosine phosphatase 1B: a paradigm for inhibitor design. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[72]  P Willett,et al.  Development and validation of a genetic algorithm for flexible docking. , 1997, Journal of molecular biology.

[73]  B. Neel,et al.  Protein tyrosine phosphatases in signal transduction. , 1997, Current opinion in cell biology.

[74]  M. Birnbaum,et al.  Expression of a Constitutively Active Akt Ser/Thr Kinase in 3T3-L1 Adipocytes Stimulates Glucose Uptake and Glucose Transporter 4 Translocation* , 1996, The Journal of Biological Chemistry.

[75]  Jerrold M. Olefsky,et al.  Protein-tyrosine Phosphatase 1B Is a Negative Regulator of Insulin- and Insulin-like Growth Factor-I-stimulated Signaling* , 1996, The Journal of Biological Chemistry.

[76]  G. Klebe,et al.  Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity. , 1994, Journal of medicinal chemistry.

[77]  D. Barford,et al.  Crystal structure of human protein tyrosine phosphatase 1B. , 1994, Science.

[78]  A. Saxena,et al.  Synthesis, biological evaluation, and quantitative structure-activity relationship analysis of [beta-(Aroylamino)ethyl]piperazines and -piperidines and [2-[(Arylamino)carbonyl]ethyl]piperazines, -pyrazinopyridoindoles, and -pyrazinoisoquinolines. A new class of potent H1 antagonists. , 1990, Journal of medicinal chemistry.

[79]  C. Kahn,et al.  Tyrosine-specific protein kinase activity is associated with the purified insulin receptor. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[80]  M. Eftink,et al.  Fluorescence quenching studies with proteins. , 1981, Analytical biochemistry.

[81]  W. Müller,et al.  The location of drug binding sites in human serum albumin. , 1981, Biochemical pharmacology.

[82]  U Kragh-Hansen,et al.  Molecular aspects of ligand binding to serum albumin. , 1981, Pharmacological reviews.

[83]  I. Sjöholm,et al.  The binding sites on human serum albumin for some nonsteroidal antiinflammatory drugs. , 1980, Molecular pharmacology.

[84]  S. Lehrer.  Solute perturbation of protein fluorescence. The quenching of the tryptophyl fluorescence of model compounds and of lysozyme by iodide ion. , 1971, Biochemistry.

[85]  M. Bower,et al.  Isothiazolidinone inhibitors of PTP1B containing imidazoles and imidazolines. , 2008, Bioorganic & medicinal chemistry letters.

[86]  R. Komers,et al.  Emerging role of Akt kinase/protein kinase B signaling in pathophysiology of diabetes and its complications. , 2005, Physiological research.

[87]  R. Hooft van Huijsduijnen,et al.  Pulling strings below the surface: hormone receptor signaling through inhibition of protein tyrosine phosphatases. , 2001, Endocrine.

[88]  Gerhard Klebe,et al.  Comparative Molecular Similarity Index Analysis (CoMSIA) to study hydrogen-bonding properties and to score combinatorial libraries , 1999, J. Comput. Aided Mol. Des..

[89]  J. Lakowicz.  Principles of fluorescence spectroscopy , 1983 .